Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex

Treatment of BCR-ABL(+) human leukemia has been significantly improved by ABL tyrosine kinase inhibitors (TKIs), but they are not curative for most patients and relapses are frequently associated with BCR-ABL mutations, warranting new targets for improved treatments. We have now demonstrated that pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Min, Turhan, Ali G., Ding, Hongxia, Lin, Qingcong, Meng, Kun, Jiang, Xiaoyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546432/
https://www.ncbi.nlm.nih.gov/pubmed/28599273
http://dx.doi.org/10.18632/oncotarget.18216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546432/
https://www.ncbi.nlm.nih.gov/pubmed/28599273
http://dx.doi.org/10.18632/oncotarget.18216

Ejemplares similares